AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26342502 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin 200 μg/kg body weight
Number of subjects: 420
Study 26342502 — intervention group
Group type: COMPARATOR
Intervention: Sulfur 10% ointment applied for three successive days
Number of subjects: 420
Study 23963058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg twice daily)
Number of subjects: 39
Study 23963058 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (600 mg twice daily)
Number of subjects: 39
Study 23963058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 21654688 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan at starting doses of 180 mg m(‐2) for *1/*1, 110 mg m(‐2) for *1/*28, and 90 mg m(‐2) for *28/*28 genotypes; escalated to 450 mg m(‐2) for *1/*1, 390 mg m(‐2) for *1/*28, and 150 mg m(‐2) for *28/*28 genotypes.
Number of subjects: 94
Study 21654688 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended dose of 180 mg m(‐2) for irinotecan in FOLFIRI.
Number of subjects: 94
Study 19047225 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 64
Study 19047225 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 64
Study 16929435 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation technique
Number of subjects: 36
Study 16929435 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 36
Study 15179649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injections of hyaluronate (5 weekly injections)
Number of subjects: 15
Study 15179649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injections of hyaluronate
Number of subjects: 15
Study 15179649 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-OA subjects)
Number of subjects: 15
Study 11431435 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tropicamide
Number of subjects: 469
Study 9751463 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucocorticoid treatment
Number of subjects: 0
Study 7516979 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (transurethral microwave therapy)
Number of subjects: 40
Study 7516979 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 40
Study 7516979 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (transurethral microwave therapy) after sham treatment
Number of subjects: 40
Study 3190622 — intervention group
Group type: COMPARATOR
Intervention: 2 mg dexamethasone orally every 6 h (starting 1 h before take-off)
Number of subjects: 26
Study 3190622 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone orally or intramuscularly every 6 h for 24 h
Number of subjects: 26
Study 31556690 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma comprising a mixture of Lavandula x intermedia (Lavandin Super), Citrus bergamia (bergamot), and Cananga odorata (ylang ylang)
Number of subjects: 42
Study 31556690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 28401564 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone daily for 10 weeks
Number of subjects: 150
Study 28401564 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 10 weeks
Number of subjects: 150
Study 26846078 — intervention group
Group type: EXPERIMENTAL
Intervention: G-immunochemical MM patients with infections (Group 1)
Number of subjects: 101
Study 26846078 — intervention group
Group type: COMPARATOR
Intervention: G-immunochemical MM patients without infections (Group 2)
Number of subjects: 101
Study 26846078 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (Group 3)
Number of subjects: 101
Study 23419135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined risk expression format (frequency and percentage)
Number of subjects: 129
Study 23419135 — intervention group
Group type: COMPARATOR
Intervention: Percentage format (e.g. 'affects 25% of people')
Number of subjects: 129
Study 23419135 — intervention group
Group type: COMPARATOR
Intervention: Frequency format (e.g. 'affects 1 in 4 people')
Number of subjects: 129
Study 21205874 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 g daily)
Number of subjects: 96
Study 21205874 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (6 mg daily)
Number of subjects: 96
Study 21205874 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Metformin and Repaglinide)
Number of subjects: 96
Study 19888336 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless Tongue Display Unit (TDU) biofeedback system
Number of subjects: 24
Study 19888336 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biofeedback)
Number of subjects: 24
Study 16534885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (800 mg) per month for 6 cycles
Number of subjects: 8
Study 16534885 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (15 mg/wk) for Crohn's disease patients
Number of subjects: 8
Study 16534885 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/kg body weight/d) for ulcerative colitis patients
Number of subjects: 8
Study 16534885 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with cyclophosphamide
Number of subjects: 8
Study 12883972 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 20
Study 12883972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10960944 — intervention group
Group type: EXPERIMENTAL
Intervention: PGV (cisplatin, gemcitabine, vinorelbine)
Number of subjects: 240
Study 10960944 — intervention group
Group type: EXPERIMENTAL
Intervention: PG (cisplatin, gemcitabine)
Number of subjects: 240
Study 10960944 — intervention group
Group type: COMPARATOR
Intervention: PV (cisplatin, vinorelbine)
Number of subjects: 240
Study 10960944 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT (cisplatin, gemcitabine, paclitaxel)
Number of subjects: 240
Study 9295453 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual education program with arthritis passport
Number of subjects: 3
Study 9295453 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials only
Number of subjects: 3
Study 9295453 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3
Study 9295453 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination of care with arthritis passport
Number of subjects: 3
Study 8040707 — intervention group
Group type: EXPERIMENTAL
Intervention: Baking soda/hydrogen peroxide dentifrice (Mentadent)
Number of subjects: 40
Study 8040707 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 percent chlorhexidine gluconate mouthrinse (Peridex)
Number of subjects: 40
Study 8040707 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard oral hygiene)
Number of subjects: 40
Study 3541623 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of percutaneous estradiol
Number of subjects: 45
Study 3541623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (200 mg) for 12 days of each cycle during the second year
Number of subjects: 45
Study 3541623 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 45
Study 3541623 — intervention group
Group type: EXPERIMENTAL
Intervention: End of study period
Number of subjects: 45
Study 29400621 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative body-mind-spirit intervention
Number of subjects: 0
Study 29400621 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy
Number of subjects: 0
Study 27534634 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS group
Number of subjects: 1228
Study 27534634 — intervention group
Group type: COMPARATOR
Intervention: IFA group
Number of subjects: 1228
Study 27534634 — intervention group
Group type: COMPARATOR
Intervention: MMN group
Number of subjects: 1228
Study 27534634 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual supplement provided (LNS)
Number of subjects: 1228
Study 27534634 — intervention group
Group type: COMPARATOR
Intervention: Actual supplement provided (IFA)
Number of subjects: 1228
Study 27534634 — intervention group
Group type: COMPARATOR
Intervention: Actual supplement provided (MMN)
Number of subjects: 1228
Study 25907407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib with a high-fat meal (study 1)
Number of subjects: 0
Study 25907407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib with esomeprazole (study 2)
Number of subjects: 0
Study 25907407 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib alone (study 2)
Number of subjects: 0
Study 23953553 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced cyclosporine (CsA)
Number of subjects: 70
Study 23953553 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) with reduced cyclosporine (CsA)
Number of subjects: 70
Study 20564081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion (n=67)
Number of subjects: 105
Study 20564081 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy alone (Control group, n=38)
Number of subjects: 105
Study 18784322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with mothers and fathers included in the breastfeeding education program
Number of subjects: 586
Study 18784322 — intervention group
Group type: COMPARATOR
Intervention: Intervention with only mothers exposed to the breastfeeding education program
Number of subjects: 586
Study 18784322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with fathers with less than 8 years of schooling
Number of subjects: 586
Study 16018426 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline-EDTA
Number of subjects: 60
Study 16018426 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 60
Study 14506579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascicular transfer
Number of subjects: 7
Study 14506579 — intervention group
Group type: COMPARATOR
Intervention: End-to-side nerve coaptation
Number of subjects: 7
Study 11076110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride treated patients
Number of subjects: 152
Study 11076110 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-sevelamer treated patients)
Number of subjects: 152
Study 8866042 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen (200 mg multiple-unit sustained release capsule) after overnight fast
Number of subjects: 38
Study 8866042 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (800 mg erodible sustained release matrix tablet) after overnight fast
Number of subjects: 38
Study 1507928 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg magnesium‐DL‐hydrogen aspartate
Number of subjects: 18
Study 1507928 — intervention group
Group type: EXPERIMENTAL
Intervention: magnesium‐L‐hydrogen aspartate
Number of subjects: 18
Study 6653132 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg flunitrazepam
Number of subjects: 18
Study 6653132 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg flunitrazepam
Number of subjects: 18
Study 6653132 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg flunitrazepam
Number of subjects: 18
Study 6653132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31724337 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-3-n-butylphthalide (NBP), 100 ml administered by intravenous injection, 2 times/day for 14 days
Number of subjects: 136
Study 31724337 — intervention group
Group type: COMPARATOR
Intervention: Routine drug therapy (Control)
Number of subjects: 136
Study 31724337 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-3-n-butylphthalide (NBP)
Number of subjects: 136
Study 30396363 — intervention group
Group type: COMPARATOR
Intervention: Medetomidine (3.0 μg/kg/h)
Number of subjects: 30
Study 30396363 — intervention group
Group type: EXPERIMENTAL
Intervention: Medetomidine (3.0 μg/kg/h) and Propofol (3.0 mg/kg/h)
Number of subjects: 30
Study 30396363 — intervention group
Group type: EXPERIMENTAL
Intervention: Medetomidine (3.0 μg/kg/h) and Propofol (6.0 mg/kg/h)
Number of subjects: 30
Study 26708017 — intervention group
Group type: EXPERIMENTAL
Intervention: MI + CBT (n = 26)
Number of subjects: 75
Study 26708017 — intervention group
Group type: EXPERIMENTAL
Intervention: NDC + CBT (n = 26)
Number of subjects: 75
Study 26708017 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WC, n = 23)
Number of subjects: 75
Study 24818209 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 30
Study 24818209 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading (Control)
Number of subjects: 30
Study 24818209 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain/swelling
Number of subjects: 30
Study 23114104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine prophylaxis (SWEN)
Number of subjects: 737
Study 23114104 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected infants
Number of subjects: 737
Study 23114104 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-uninfected infants
Number of subjects: 737
Study 23114104 — intervention group
Group type: COMPARATOR
Intervention: Baseline prevalence
Number of subjects: 737
Study 23114104 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of HIV infection
Number of subjects: 737
Study 19874329 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine plus 5 mg/day desloratadine (suppression group, n = 8)
Number of subjects: 15
Study 19874329 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/day desloratadine alone (control group, n = 7)
Number of subjects: 15
Study 17585215 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 40
Study 17585215 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 40
Study 16232342 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation and noninvasive MV via facial mask immediately after PIC window
Number of subjects: 90
Study 16232342 — intervention group
Group type: COMPARATOR
Intervention: Invasive MV received continuously after PIC window by using conventional weaning technique
Number of subjects: 90
Study 12011967 — intervention group
Group type: EXPERIMENTAL
Intervention: HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) 1 g, twice daily for 6 months
Number of subjects: 20
Study 12011967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12011967 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 20
Study 10930636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 0.5 mg kg(‐1)
Number of subjects: 45
Study 10930636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg kg(‐1)
Number of subjects: 45
Study 10930636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9420536 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical PUVA (n = 28)
Number of subjects: 281
Study 9420536 — intervention group
Group type: EXPERIMENTAL
Intervention: 311-nm UV-B radiation (n = 78)
Number of subjects: 281
Study 9420536 — intervention group
Group type: COMPARATOR
Intervention: 311-nm UV-B radiation (n = 60, followed for 3 months)
Number of subjects: 281
Study 9420536 — intervention group
Group type: COMPARATOR
Intervention: 311-nm UV-B radiation (n = 51, followed for 12 months)
Number of subjects: 281
Study 8250358 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 ml per m2 of body surface area of carbonated 1% lignocaine, 0.25% bupivacaine or a 1 to 1 mixture of both.
Number of subjects: 120
Study 8250358 — intervention group
Group type: COMPARATOR
Intervention: 12.5 ml.m‐2 of carbonated 2% lignocaine, 0.5% bupivacaine or a 1 to 1 mixture of both.
Number of subjects: 120
Study 4025773 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 50
Study 4025773 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 50
Study 29682022 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate 40 mg injected into each level (Group 1)
Number of subjects: 100
Study 29682022 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency needle applied to the facet joint (Group 2)
Number of subjects: 100
Study 27769202 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT) - 10,000 Lux
Number of subjects: 84
Study 27769202 — intervention group
Group type: COMPARATOR
Intervention: Control light condition - 200 Lux
Number of subjects: 84
Study 27769202 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 84
Study 25498777 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Perception of Intensity of Urgency Scale (PPIUS) - Total Urgency and Frequency Score (TUFS)
Number of subjects: 901
Study 25498777 — intervention group
Group type: EXPERIMENTAL
Intervention: Other PPIUS-derived scores
Number of subjects: 901
Study 23444895 — intervention group
Group type: EXPERIMENTAL
Intervention: Green calorie label
Number of subjects: 0
Study 23444895 — intervention group
Group type: COMPARATOR
Intervention: Red calorie label
Number of subjects: 0
Study 23444895 — intervention group
Group type: COMPARATOR
Intervention: White calorie label
Number of subjects: 0
Study 19900763 — intervention group
Group type: EXPERIMENTAL
Intervention: AlcoholEdu
Number of subjects: 82
Study 19900763 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Chug
Number of subjects: 82
Study 19900763 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 82
Study 18491685 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Health Enhancement Support System (CHESS), a Web‐based information and support scheme
Number of subjects: 0
Study 18491685 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16817205 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-item Geriatric Depression Scale (GDS)
Number of subjects: 57
Study 16817205 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-item Hamilton Depression Rating Scale (HDRS)
Number of subjects: 57
Study 16817205 — intervention group
Group type: EXPERIMENTAL
Intervention: GDS
Number of subjects: 57
Study 14620073 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participation (for randomized participants)
Number of subjects: 58
Study 14620073 — intervention group
Group type: COMPARATOR
Intervention: Screening visit (for non-participants)
Number of subjects: 58
Study 11063182 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) 1.5 mega-units diluted in 100 mls of normal saline infused over 60 minutes (Group A)
Number of subjects: 120
Study 11063182 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) - AMI patients who did not receive SK
Number of subjects: 120
Study 8843961 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (bleomycin, vincristine, mitolactol, methotrexate, 3 courses)
Number of subjects: 50
Study 8843961 — intervention group
Group type: COMPARATOR
Intervention: Preoperative irradiation (telecobalt, followed by surgery)
Number of subjects: 50
Study 1441001 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization with a brace
Number of subjects: 71
Study 1441001 — intervention group
Group type: COMPARATOR
Intervention: Immobilization with plaster cast
Number of subjects: 71
Study 31650354 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily group (DG) - melatonin supplement taken between 22:00 and 23:00 for 3 consecutive days
Number of subjects: 67
Study 31650354 — intervention group
Group type: COMPARATOR
Intervention: Acute group (AG) - melatonin supplement taken after the second measure on the second day
Number of subjects: 67
Study 28954297 — intervention group
Group type: EXPERIMENTAL
Intervention: AT
Number of subjects: 1512
Study 28954297 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT
Number of subjects: 1512
Study 28954297 — intervention group
Group type: COMPARATOR
Intervention: AC→T
Number of subjects: 1512
Study 28954297 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting PN, older age, obesity, mastectomy, greater number of positive nodes
Number of subjects: 1512
Study 28954297 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse PN symptoms at 24 months
Number of subjects: 1512
Study 28404197 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercaptopurine (1 mg/kg bodyweight, rounded to nearest 25 mg)
Number of subjects: 240
Study 28404197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 28404197 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercaptopurine (in smokers)
Number of subjects: 240
Study 28404197 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in smokers)
Number of subjects: 240
Study 28404197 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercaptopurine (in non-smokers)
Number of subjects: 240
Study 28404197 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in non-smokers)
Number of subjects: 240
Study 28404197 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Number of subjects: 240
Study 25022690 — intervention group
Group type: EXPERIMENTAL
Intervention: H61-fermented milk (10^10 cfu of strain H61/d)
Number of subjects: 23
Study 25022690 — intervention group
Group type: COMPARATOR
Intervention: Conventional yogurt (10^10 cfu of Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus thermophilus per day)
Number of subjects: 23
Study 25022690 — intervention group
Group type: EXPERIMENTAL
Intervention: H61-fermented milk and Conventional yogurt
Number of subjects: 23
Study 22874843 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium load
Number of subjects: 15
Study 22874843 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sodium load
Number of subjects: 15
Study 22874843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet
Number of subjects: 15
Study 22874843 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet
Number of subjects: 15
Study 22874843 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of prouroguanylin
Number of subjects: 15
Study 22874843 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of proguanylin
Number of subjects: 15
Study 20688454 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based education
Number of subjects: 0
Study 20688454 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-based education
Number of subjects: 0